Since canagliflozin was shown to inhibit hyperglycemia and hyperinsulinemia without adverse consequences [10], cotreatment with Akt or PI3K inhibitors that inhibit Akt2 in insulin-responsive tissues should be considered. This evidence concerns the gene AKT1 and Hyperinsulinemia.